Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CPN1 | P15169 | 2/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825809 | 1.00 | KCNH2 (0.41) | KCNH2EPHX1CPN1CPB2SLC6A1 | |
| SCHEMBL31109672 | 1.00 | KCNH2 (0.41) | KCNH2EPHX1CPN1CPB2SLC6A1 | |
| SCHEMBL6371477 | 0.89 | CPN1 (0.45) | EPHX1CPN1CPB2SLC6A1SLC6A11 | |
| SCHEMBL384885 | 0.89 | CPN1 (0.45) | EPHX1CPN1CPB2SLC6A1SLC6A11 | |
| SCHEMBL384884 | 0.89 | CPN1 (0.45) | EPHX1CPN1CPB2SLC6A1SLC6A11 | |
| SCHEMBL6371199 | 0.89 | EPHX1 (0.47) | EPHX1CPN1CPB2GABRA5GABRB2 | |
| SCHEMBL384923 | 0.89 | EPHX1 (0.47) | EPHX1CPN1CPB2GABRA5GABRB2 | |
| SCHEMBL384924 | 0.89 | EPHX1 (0.47) | EPHX1CPN1CPB2GABRA5GABRB2 | |
| SCHEMBL1801065 | 0.84 | KCNH2 (0.40) | KCNH2EPHX1SLC6A1GABRA5GABRB2 | |
| SCHEMBL1801069 | 0.84 | KCNH2 (0.40) | KCNH2EPHX1SLC6A1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | claimed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | claimed |
| US-20250354176-A1 | TARGETING PEPTIDE TO DELIVER A COMPOUND TO OOCYTES | PENN STATE RES FOUND (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4622996-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | King's College London (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-12391962-B2 | Targeting peptide to deliver a compound to oocytes | THE PENN STATE RESEARCH FOUNDATION (PA) | 2025-08-19 | — | — | US | disclosed |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2024110757-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | KING'S COLLEGE LONDON (GB) | 2024-05-30 | — | — | WO | disclosed |
| US-11976382-B2 | Nucleic acid based biosensor and methods thereof | BOISE STATE UNIVERSITY (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| US-11807677-B2 | Microbe-binding molecules and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-07 | — | — | US | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2013071049-A1 | GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY | TRUSTEES OF BOSTON COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130064895-A1 | Amphiphilic Peptides and Peptide Particles | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013028843-A1 | PEPTIDE NANOPARTICLES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012177986-A2 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES (IN) | 2012-12-27 | — | — | WO | disclosed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | disclosed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | KCNH2 4148/4885EPHX1 2760/4885CPN1 696/4885 |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | KCNH2 4290/4885EPHX1 4130/4885CPN1 582/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | KCNH2 4179/4885EPHX1 1009/4885CPN1 1765/4885 |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | KCNH2 4148/4885EPHX1 2760/4885CPN1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.